Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Gains from Investment Securities (2016 - 2026)

Neuroone Medical Technologies filings provide 9 years of Gains from Investment Securities readings, the most recent being $8271.0 for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities fell 2.85% to $8271.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$364823.0, a 4384.98% decrease, with the full-year FY2025 number at $1.0 million, down 63.97% from a year prior.
  • Gains from Investment Securities hit $8271.0 in Q1 2026 for Neuroone Medical Technologies, up from $3632.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $3.3 million in Q2 2025 to a low of -$389445.0 in Q4 2024.
  • Median Gains from Investment Securities over the past 5 years was $12719.0 (2025), compared with a mean of $412757.7.
  • The widest YoY moves for Gains from Investment Securities: up 235153.17% in 2024, down 133.55% in 2024.
  • Neuroone Medical Technologies' Gains from Investment Securities stood at $97536.0 in 2022, then surged by 1089.99% to $1.2 million in 2023, then tumbled by 133.55% to -$389445.0 in 2024, then skyrocketed by 100.93% to $3632.0 in 2025, then skyrocketed by 127.73% to $8271.0 in 2026.
  • The last three reported values for Gains from Investment Securities were $8271.0 (Q1 2026), $3632.0 (Q4 2025), and $12719.0 (Q3 2025) per Business Quant data.